Evidence map›Paper›PMID 33123211›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2020

Molecular Targets and Pathways Contributing to the Effects of Wenxin Keli on Atrial Fibrillation Based on a Network Pharmacology Approach.

Yujie Zhang, Xiaolin Zhang, Xi Zhang, Yi Cai, Minghui Cheng, Chenghui Yan, Yaling Han

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Network Pharmacology and Pharmacological Mechanism of CV-3 in Atrial Fibrillation.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Yujie ZhangLiaoning University of Traditional Chinese Medicine, Liaoning, Shenyang 110847, China.
Xiaolin ZhangCardiovascular Research Institute and Department of Cardiology, The General Hospital of Northern Theatre Command, Liaoning, Shenyang 110840, China.
Xi ZhangCardiovascular Research Institute and Department of Cardiology, The General Hospital of Northern Theatre Command, Liaoning, Shenyang 110840, China.
Yi CaiCardiovascular Research Institute and Department of Cardiology, The General Hospital of Northern Theatre Command, Liaoning, Shenyang 110840, China.
Minghui ChengCardiovascular Research Institute and Department of Cardiology, The General Hospital of Northern Theatre Command, Liaoning, Shenyang 110840, China.
Chenghui YanCardiovascular Research Institute and Department of Cardiology, The General Hospital of Northern Theatre Command, Liaoning, Shenyang 110840, China.
Yaling HanLiaoning University of Traditional Chinese Medicine, Liaoning, Shenyang 110847, China.ORCID https://orcid.org/0000-0002-4719-6552
Cardiovascular Institute Hospital · JPLiaoning University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) is the most common sustained arrhythmia and is associated with high rates of mortality and morbidity. The traditional Chinese medicine Wenxin Keli (WXKL) can effectively improve clinical symptoms and is safe for the treatment of AF. However, the active substances in WXKL and the molecular mechanisms underlying its effects on AF remain unclear. In this study, the bioactive compounds in WXKL, as well as their molecular targets and associated pathways, were evaluated by systems pharmacology. MATERIALS AND

methodsChemical constituents and potential targets of WXKL were obtained via the Traditional Chinese Medicine Systems Pharmacology (TCMSP). The TTD, DrugBank, DisGeNET, and GeneCards databases were used to collect AF-related target genes. Based on common targets related to both AF and WXKL, a protein interaction network was generated using the STRING database. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGGs) pathway enrichment analyses were performed. Network diagrams of the active component-target and protein-protein interactions (PPIs) were constructed using Cytoscape.

resultsA total of 30 active ingredients in WXKL and 219 putative target genes were screened, including 83 genes identified as therapeutic targets in AF; these overlapping genes were considered candidate targets for subsequent analyses. The effect of treating AF was mainly correlated with the regulation of target proteins, such as IL-6, TNF, AKT1, VEGFA, CXCL8, TP53, CCL2, MMP9, CASP3, and NOS3. GO and KEGG analyses revealed that these targets are associated with the inflammatory response, oxidative stress reaction, immune regulation, cardiac energy metabolism, serotonergic synapse, and other pathways.

conclusionsThis study demonstrated the multicomponent, multitarget, and multichannel characteristics of WXKL, providing a basis for further studies of the mechanism underlying the beneficial effects of WXKL in AF.

Identifiers

PMID33123211
PMCPMC7586041
OpenAlexW3092378521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.